Toggle Navigation
Each
Pod
Each
Pod
Podcasts
Episodes
Genres
Login
Oncology Times - OncTimes Talk
Resectable Stage III Melanoma: Unprecedented Survival Benefit With Pure Checkpoint Inhibitor Neoadjuvant Therapy
Resectable Stage III Melanoma: Unprecedented Survival Benefit With Pure Checkpoint Inhibitor Neoadjuvant Therapy
Author
Oncology Times
Published
Wed 23 Oct 2024
Episode Link
https://traffic.libsyn.com/secure/otbroadcastsarchives/OT_POD_EP109_101524.mp3.mp3
Share to:
